STOCK TITAN

[Form 4] Cumberland Pharmaceuticals Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

SEC Form 4 filing dated 07/11/2025 reports a series of open-market purchases of Cumberland Pharmaceuticals Inc. (CPIX) common stock by director Caroline Young.

Transaction details:

  • 20 separate buy transactions executed from 06/02/2025 to 06/30/2025.
  • Total shares acquired: 84 (nineteen lots of 4 shares and one lot of 8 shares).
  • Price range: $2.60 – $6.00 per share.
  • Weighted-average purchase price: approximately $4.81 per share (derived from disclosed price and share data).
  • Total cost: about $403.60.

All trades were automatically executed under a Rule 10b5-1 trading plan adopted on 11/14/2024, as noted in the Explanation of Responses.

Following the reported transactions Ms. Young’s direct beneficial ownership stands at 32,653 CPIX shares. No derivative security activity was reported, and the filing indicates that Ms. Young continues to serve as a director of the company.

The filing does not provide information on company operations, earnings or additional insider activity. The share-price pattern shows a steady decline over the month—from $5.20 on 06/02 to $2.74 on 06/30—suggesting the purchases occurred during a period of price weakness.

Modulo SEC Form 4 datato 11/07/2025 riporta una serie di acquisti sul mercato aperto di azioni ordinarie di Cumberland Pharmaceuticals Inc. (CPIX) effettuati da Caroline Young, membro del consiglio di amministrazione.

Dettagli della transazione:

  • 20 acquisti distinti eseguiti dal 02/06/2025 al 30/06/2025.
  • Totale azioni acquisite: 84 (diciannove lotti da 4 azioni e un lotto da 8 azioni).
  • Fascia di prezzo: da $2,60 a $6,00 per azione.
  • Prezzo medio ponderato di acquisto: circa $4,81 per azione (calcolato dai dati di prezzo e quantità dichiarati).
  • Costo totale: circa $403,60.

Tutte le operazioni sono state eseguite automaticamente secondo un piano di trading Rule 10b5-1 adottato il 14/11/2024, come indicato nella spiegazione delle risposte.

Dopo queste transazioni, la proprietà diretta di Ms. Young ammonta a 32.653 azioni CPIX. Non sono state segnalate attività su strumenti derivati e il modulo indica che Ms. Young continua a ricoprire il ruolo di direttrice dell’azienda.

Il documento non fornisce informazioni sulle operazioni aziendali, sugli utili o su altre attività degli insider. L’andamento del prezzo delle azioni mostra un calo costante nel corso del mese — da $5,20 il 02/06 a $2,74 il 30/06 — suggerendo che gli acquisti siano avvenuti in un periodo di debolezza del prezzo.

Presentación del Formulario SEC 4 con fecha 11/07/2025 informa sobre una serie de compras en el mercado abierto de acciones comunes de Cumberland Pharmaceuticals Inc. (CPIX) realizadas por la directora Caroline Young.

Detalles de la transacción:

  • 20 compras separadas realizadas desde el 02/06/2025 hasta el 30/06/2025.
  • Total de acciones adquiridas: 84 (diecinueve lotes de 4 acciones y un lote de 8 acciones).
  • Rango de precios: $2.60 – $6.00 por acción.
  • Precio promedio ponderado de compra: aproximadamente $4.81 por acción (calculado a partir de los datos de precio y cantidad divulgados).
  • Costo total: alrededor de $403.60.

Todas las operaciones se ejecutaron automáticamente bajo un plan de negociación Rule 10b5-1 adoptado el 14/11/2024, según se indica en la explicación de respuestas.

Tras las transacciones reportadas, la propiedad directa beneficiaria de la Sra. Young es de 32,653 acciones CPIX. No se reportó actividad con valores derivados y el informe indica que la Sra. Young continúa sirviendo como directora de la empresa.

El informe no proporciona información sobre las operaciones de la empresa, ganancias u otra actividad interna adicional. El patrón del precio de las acciones muestra una caída constante durante el mes — de $5.20 el 02/06 a $2.74 el 30/06 — lo que sugiere que las compras se realizaron durante un periodo de debilidad en el precio.

2025년 7월 11일자 SEC Form 4 제출서에는 이사 캐롤라인 영이 Cumberland Pharmaceuticals Inc.(CPIX) 보통주를 장내에서 매수한 일련의 거래가 보고되어 있습니다.

거래 내역:

  • 2025년 6월 2일부터 6월 30일까지 총 20건의 개별 매수 거래가 이루어졌습니다.
  • 총 매수 주식 수: 84주 (19건은 4주씩, 1건은 8주).
  • 주당 가격 범위: $2.60에서 $6.00 사이.
  • 가중 평균 매입 단가: 약 $4.81 (공개된 가격과 주식 수를 바탕으로 산출).
  • 총 매입 비용: 약 $403.60.

모든 거래는 2024년 11월 14일 채택된 Rule 10b5-1 거래 계획에 따라 자동으로 실행되었으며, 답변 설명에 명시되어 있습니다.

보고된 거래 후 캐롤라인 영 이사의 직접 실소유 주식은 32,653주 CPIX입니다. 파생상품 관련 거래는 보고되지 않았으며, 그녀가 여전히 회사의 이사로 재직 중임을 나타냅니다.

제출 서류에는 회사 운영, 수익 또는 추가 내부자 활동에 관한 정보는 포함되어 있지 않습니다. 주가 추이는 6월 한 달 동안 꾸준히 하락했음을 보여주며 — 6월 2일 $5.20에서 6월 30일 $2.74까지 — 매수는 가격 약세 기간에 이루어진 것으로 보입니다.

Dépôt du formulaire SEC 4 daté du 11/07/2025 rapporte une série d’achats sur le marché libre d’actions ordinaires de Cumberland Pharmaceuticals Inc. (CPIX) réalisés par la directrice Caroline Young.

Détails de la transaction :

  • 20 achats distincts effectués du 02/06/2025 au 30/06/2025.
  • Total des actions acquises : 84 (dix-neuf lots de 4 actions et un lot de 8 actions).
  • Fourchette de prix : entre 2,60 $ et 6,00 $ par action.
  • Prix d’achat moyen pondéré : environ 4,81 $ par action (calculé à partir des données de prix et de quantité divulguées).
  • Coût total : environ 403,60 $.

Toutes les transactions ont été exécutées automatiquement dans le cadre d’un plan de trading Rule 10b5-1 adopté le 14/11/2024, comme indiqué dans l’explication des réponses.

À la suite des transactions déclarées, la détention directe de Mme Young s’élève à 32 653 actions CPIX. Aucune activité sur titres dérivés n’a été signalée, et le dépôt indique que Mme Young continue d’occuper le poste de directrice de la société.

Le dépôt ne fournit pas d’informations sur les opérations de la société, les résultats financiers ou d’autres activités d’initiés. La tendance du cours de l’action montre une baisse régulière au cours du mois — de 5,20 $ le 02/06 à 2,74 $ le 30/06 — ce qui suggère que les achats ont eu lieu pendant une période de faiblesse des prix.

SEC Formular 4 Einreichung vom 11.07.2025 berichtet über eine Reihe von Käufen von Stammaktien der Cumberland Pharmaceuticals Inc. (CPIX) im offenen Markt durch Direktorin Caroline Young.

Transaktionsdetails:

  • 20 einzelne Kauftransaktionen ausgeführt vom 02.06.2025 bis 30.06.2025.
  • Gesamtanzahl erworbener Aktien: 84 (neunzehn Lose zu je 4 Aktien und ein Los zu 8 Aktien).
  • Preisspanne: 2,60 $ bis 6,00 $ pro Aktie.
  • Gewichteter durchschnittlicher Kaufpreis: etwa 4,81 $ pro Aktie (basierend auf den angegebenen Preis- und Stückzahlen).
  • Gesamtkosten: ca. 403,60 $.

Alle Trades wurden automatisch im Rahmen eines Rule 10b5-1 Handelsplans, der am 14.11.2024 angenommen wurde, ausgeführt, wie in der Erläuterung der Antworten angegeben.

Nach den gemeldeten Transaktionen hält Frau Young direkt 32.653 CPIX-Aktien. Es wurden keine Derivatgeschäfte gemeldet, und die Einreichung bestätigt, dass Frau Young weiterhin als Direktorin des Unternehmens tätig ist.

Die Einreichung enthält keine Informationen zu Unternehmensbetrieb, Gewinnzahlen oder weiteren Insideraktivitäten. Das Kursmuster zeigt einen stetigen Rückgang im Verlauf des Monats — von 5,20 $ am 02.06. auf 2,74 $ am 30.06. — was darauf hindeutet, dass die Käufe in einer Phase von Kursrückgängen stattfanden.

Positive
  • Director increased direct holdings by 84 shares, bringing total ownership to 32,653 shares.
  • All transactions executed under a pre-arranged Rule 10b5-1 plan, demonstrating compliance with insider-trading regulations.
Negative
  • Purchase size is immaterial relative to typical trading volumes and likely has no meaningful impact on insider ownership percentage.
  • Disclosed share prices fell from $5.20 to $2.74 during the transaction window, reflecting significant share-price weakness.

Insights

TL;DR: Small automatic insider buys (84 shares) under 10b5-1 plan; positive signal limited by immaterial size and falling prices.

The Form 4 indicates consistent daily buying by director Caroline Young but at very low volume—84 shares over a month is negligible versus typical public float, limiting any valuation impact. The purchases were pre-scheduled, reducing informational content compared with discretionary buying. However, the director’s ownership increased and now totals 32,653 shares, which may marginally align interests with shareholders. Notably, traded prices dropped more than 50% during the period ($5.94 to $2.60), implying the company’s stock was under pressure while the plan was executed. From a portfolio perspective the filing is informational, not actionable; it neither alters earnings outlook nor capital structure.

Modulo SEC Form 4 datato 11/07/2025 riporta una serie di acquisti sul mercato aperto di azioni ordinarie di Cumberland Pharmaceuticals Inc. (CPIX) effettuati da Caroline Young, membro del consiglio di amministrazione.

Dettagli della transazione:

  • 20 acquisti distinti eseguiti dal 02/06/2025 al 30/06/2025.
  • Totale azioni acquisite: 84 (diciannove lotti da 4 azioni e un lotto da 8 azioni).
  • Fascia di prezzo: da $2,60 a $6,00 per azione.
  • Prezzo medio ponderato di acquisto: circa $4,81 per azione (calcolato dai dati di prezzo e quantità dichiarati).
  • Costo totale: circa $403,60.

Tutte le operazioni sono state eseguite automaticamente secondo un piano di trading Rule 10b5-1 adottato il 14/11/2024, come indicato nella spiegazione delle risposte.

Dopo queste transazioni, la proprietà diretta di Ms. Young ammonta a 32.653 azioni CPIX. Non sono state segnalate attività su strumenti derivati e il modulo indica che Ms. Young continua a ricoprire il ruolo di direttrice dell’azienda.

Il documento non fornisce informazioni sulle operazioni aziendali, sugli utili o su altre attività degli insider. L’andamento del prezzo delle azioni mostra un calo costante nel corso del mese — da $5,20 il 02/06 a $2,74 il 30/06 — suggerendo che gli acquisti siano avvenuti in un periodo di debolezza del prezzo.

Presentación del Formulario SEC 4 con fecha 11/07/2025 informa sobre una serie de compras en el mercado abierto de acciones comunes de Cumberland Pharmaceuticals Inc. (CPIX) realizadas por la directora Caroline Young.

Detalles de la transacción:

  • 20 compras separadas realizadas desde el 02/06/2025 hasta el 30/06/2025.
  • Total de acciones adquiridas: 84 (diecinueve lotes de 4 acciones y un lote de 8 acciones).
  • Rango de precios: $2.60 – $6.00 por acción.
  • Precio promedio ponderado de compra: aproximadamente $4.81 por acción (calculado a partir de los datos de precio y cantidad divulgados).
  • Costo total: alrededor de $403.60.

Todas las operaciones se ejecutaron automáticamente bajo un plan de negociación Rule 10b5-1 adoptado el 14/11/2024, según se indica en la explicación de respuestas.

Tras las transacciones reportadas, la propiedad directa beneficiaria de la Sra. Young es de 32,653 acciones CPIX. No se reportó actividad con valores derivados y el informe indica que la Sra. Young continúa sirviendo como directora de la empresa.

El informe no proporciona información sobre las operaciones de la empresa, ganancias u otra actividad interna adicional. El patrón del precio de las acciones muestra una caída constante durante el mes — de $5.20 el 02/06 a $2.74 el 30/06 — lo que sugiere que las compras se realizaron durante un periodo de debilidad en el precio.

2025년 7월 11일자 SEC Form 4 제출서에는 이사 캐롤라인 영이 Cumberland Pharmaceuticals Inc.(CPIX) 보통주를 장내에서 매수한 일련의 거래가 보고되어 있습니다.

거래 내역:

  • 2025년 6월 2일부터 6월 30일까지 총 20건의 개별 매수 거래가 이루어졌습니다.
  • 총 매수 주식 수: 84주 (19건은 4주씩, 1건은 8주).
  • 주당 가격 범위: $2.60에서 $6.00 사이.
  • 가중 평균 매입 단가: 약 $4.81 (공개된 가격과 주식 수를 바탕으로 산출).
  • 총 매입 비용: 약 $403.60.

모든 거래는 2024년 11월 14일 채택된 Rule 10b5-1 거래 계획에 따라 자동으로 실행되었으며, 답변 설명에 명시되어 있습니다.

보고된 거래 후 캐롤라인 영 이사의 직접 실소유 주식은 32,653주 CPIX입니다. 파생상품 관련 거래는 보고되지 않았으며, 그녀가 여전히 회사의 이사로 재직 중임을 나타냅니다.

제출 서류에는 회사 운영, 수익 또는 추가 내부자 활동에 관한 정보는 포함되어 있지 않습니다. 주가 추이는 6월 한 달 동안 꾸준히 하락했음을 보여주며 — 6월 2일 $5.20에서 6월 30일 $2.74까지 — 매수는 가격 약세 기간에 이루어진 것으로 보입니다.

Dépôt du formulaire SEC 4 daté du 11/07/2025 rapporte une série d’achats sur le marché libre d’actions ordinaires de Cumberland Pharmaceuticals Inc. (CPIX) réalisés par la directrice Caroline Young.

Détails de la transaction :

  • 20 achats distincts effectués du 02/06/2025 au 30/06/2025.
  • Total des actions acquises : 84 (dix-neuf lots de 4 actions et un lot de 8 actions).
  • Fourchette de prix : entre 2,60 $ et 6,00 $ par action.
  • Prix d’achat moyen pondéré : environ 4,81 $ par action (calculé à partir des données de prix et de quantité divulguées).
  • Coût total : environ 403,60 $.

Toutes les transactions ont été exécutées automatiquement dans le cadre d’un plan de trading Rule 10b5-1 adopté le 14/11/2024, comme indiqué dans l’explication des réponses.

À la suite des transactions déclarées, la détention directe de Mme Young s’élève à 32 653 actions CPIX. Aucune activité sur titres dérivés n’a été signalée, et le dépôt indique que Mme Young continue d’occuper le poste de directrice de la société.

Le dépôt ne fournit pas d’informations sur les opérations de la société, les résultats financiers ou d’autres activités d’initiés. La tendance du cours de l’action montre une baisse régulière au cours du mois — de 5,20 $ le 02/06 à 2,74 $ le 30/06 — ce qui suggère que les achats ont eu lieu pendant une période de faiblesse des prix.

SEC Formular 4 Einreichung vom 11.07.2025 berichtet über eine Reihe von Käufen von Stammaktien der Cumberland Pharmaceuticals Inc. (CPIX) im offenen Markt durch Direktorin Caroline Young.

Transaktionsdetails:

  • 20 einzelne Kauftransaktionen ausgeführt vom 02.06.2025 bis 30.06.2025.
  • Gesamtanzahl erworbener Aktien: 84 (neunzehn Lose zu je 4 Aktien und ein Los zu 8 Aktien).
  • Preisspanne: 2,60 $ bis 6,00 $ pro Aktie.
  • Gewichteter durchschnittlicher Kaufpreis: etwa 4,81 $ pro Aktie (basierend auf den angegebenen Preis- und Stückzahlen).
  • Gesamtkosten: ca. 403,60 $.

Alle Trades wurden automatisch im Rahmen eines Rule 10b5-1 Handelsplans, der am 14.11.2024 angenommen wurde, ausgeführt, wie in der Erläuterung der Antworten angegeben.

Nach den gemeldeten Transaktionen hält Frau Young direkt 32.653 CPIX-Aktien. Es wurden keine Derivatgeschäfte gemeldet, und die Einreichung bestätigt, dass Frau Young weiterhin als Direktorin des Unternehmens tätig ist.

Die Einreichung enthält keine Informationen zu Unternehmensbetrieb, Gewinnzahlen oder weiteren Insideraktivitäten. Das Kursmuster zeigt einen stetigen Rückgang im Verlauf des Monats — von 5,20 $ am 02.06. auf 2,74 $ am 30.06. — was darauf hindeutet, dass die Käufe in einer Phase von Kursrückgängen stattfanden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Young Caroline

(Last) (First) (Middle)
1600 WEST END AVENUE
SUITE 1300

(Street)
NASHVILLE TN 37203

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/02/2025 P V 4(1) A $5.2 32,573 D
Common Stock 06/03/2025 P V 4(1) A $5.61 32,577 D
Common Stock 06/04/2025 P V 4(1) A $5.75 32,581 D
Common Stock 06/05/2025 P V 4(1) A $5.46 32,585 D
Common Stock 06/06/2025 P V 4(1) A $5.57 32,589 D
Common Stock 06/09/2025 P V 4(1) A $5.94 32,593 D
Common Stock 06/10/2025 P V 4(1) A $6 32,597 D
Common Stock 06/11/2025 P V 4(1) A $5.57 32,601 D
Common Stock 06/12/2025 P V 4(1) A $5.67 32,605 D
Common Stock 06/13/2025 P V 4(1) A $5.81 32,609 D
Common Stock 06/16/2025 P V 4(1) A $5.32 32,613 D
Common Stock 06/17/2025 P V 4(1) A $5.61 32,617 D
Common Stock 06/18/2025 P V 4(1) A $5.52 32,621 D
Common Stock 06/20/2025 P V 4(1) A $5.29 32,625 D
Common Stock 06/23/2025 P V 4(1) A $4.61 32,629 D
Common Stock 06/24/2025 P V 4(1) A $3.91 32,633 D
Common Stock 06/25/2025 P V 4(1) A $3.27 32,637 D
Common Stock 06/26/2025 P V 4(1) A $2.71 32,641 D
Common Stock 06/27/2025 P V 4(1) A $2.6 32,645 D
Common Stock 06/30/2025 P V 8(1) A $2.74 32,653 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.
Remarks:
Caroline Young by /s/ John Hamm as attorney-in-fact 07/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CPIX shares did Caroline Young purchase according to the Form 4?

She bought 84 shares between 06/02/2025 and 06/30/2025.

What was the price range of Caroline Young’s CPIX purchases?

Prices ranged from $2.60 to $6.00 per share.

What is Caroline Young’s total ownership in Cumberland Pharmaceuticals after the transactions?

She now directly owns 32,653 CPIX shares.

Were the transactions conducted under a 10b5-1 trading plan?

Yes. The filing states they were executed under a Rule 10b5-1 plan adopted on 11/14/2024.

What role does Caroline Young hold at Cumberland Pharmaceuticals?

She is listed as a Director of the company.
Cumberland Pharmaceuticals Inc

NASDAQ:CPIX

CPIX Rankings

CPIX Latest News

CPIX Latest SEC Filings

CPIX Stock Data

47.13M
8.75M
44.47%
22.13%
2.25%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE,